Cite
HARVARD Citation
Kumar, S. et al. (2021). A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert opinion on biological therapy. pp. 675-686. [Online].